e-ISSN: 3108-2599

International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Clinical Artificial Intelligence in Oncology: Opportunities, Challenges, and Future Directions

Mrs. Shalini Gupta[1], Dr. Mohan Krishnan[2], Mr. Naveen Yadav[3]

[1]Assistant Professor Department of Clinical Pharmacy, Central Institute of Health Sciences, Bhopal, India shalini.g92@gmail.com

[2]Professor Department of Pharmacology, Central Institute of Health Sciences, Bhopal, India mohan.krishnan65@gmail.com

[3]Associate Professor Department of Pharmaceutical Analysis, Central Institute of Health Sciences, Bhopal, India naveenyadav09@gmail.com

ABSTRACT

Artificial intelligence (AI) is rapidly transforming clinical oncology by enabling data-driven approaches to cancer diagnosis, prognosis, treatment planning, therapeutic monitoring, and long-term survivorship care. The growing availability of electronic health records, medical imaging, digital pathology, genomic sequencing, molecular diagnostics, and real-world clinical data has created unprecedented opportunities for AI-driven precision medicine. Machine learning, deep learning, natural language processing, computer vision, multimodal learning, graph neural networks, and foundation models now support clinicians in interpreting complex biomedical information that exceeds conventional analytical capabilities. AI-assisted systems have demonstrated remarkable performance in tumor detection, disease classification, prognostic prediction, radiogenomics, computational pathology, treatment optimization, immunotherapy response prediction, adaptive radiation planning, and clinical decision support. In addition, emerging technologies such as generative AI, federated learning, explainable AI, and digital health platforms are expanding the role of intelligent clinical systems throughout the oncology care continuum. Despite these advances, widespread clinical implementation remains limited by challenges involving data quality, interoperability, algorithmic bias, transparency, cybersecurity, ethical governance, regulatory approval, clinician acceptance, and healthcare equity. This review discusses the current landscape of clinical artificial intelligence in oncology, highlighting major opportunities, existing limitations, technological innovations, and future directions that will shape the next generation of precision cancer care.[1]

Keywords: *Artificial intelligence, Clinical oncology, Precision medicine, Machine learning, Deep learning, Clinical decision support, Digital pathology, Radiogenomics, Cancer informatics, Precision oncology.*

Article History
Received: 10 December 2025; **Accepted:** 18 December 2025; **Published:** 28 December 2025

Citation
Gupta S., (2025). Clinical Artificial Intelligence in Oncology: Opportunities, Challenges, and Future Directions. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 34-40.*
DOI: https://doi.org/10.65477/2026.v.1i.5.05

1. Introduction

Cancer continues to represent one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular biology, targeted therapies, immunotherapy, and precision medicine. The biological complexity of malignant diseases, characterized by genomic instability, tumor heterogeneity, immune interactions, metabolic reprogramming, and dynamic tumor evolution, presents substantial challenges for clinical decision-making. Patients with similar histopathological diagnoses often exhibit markedly different responses to therapy, recurrence patterns, and survival outcomes, highlighting the limitations of traditional population-based treatment strategies.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical information through

e-ISSN: 3108-2599

radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory investigations, wearable technologies, and electronic health records. Although these diverse data sources collectively provide comprehensive insights into tumor biology, their interpretation frequently exceeds the capacity of conventional statistical approaches and routine clinical workflows.[3]

Artificial intelligence has emerged as one of the most promising technologies capable of transforming complex biomedical datasets into clinically actionable knowledge. By identifying hidden patterns within multidimensional data, AI supports accurate diagnosis, individualized prognostic prediction, therapeutic optimization, toxicity assessment, and longitudinal patient monitoring. Rather than replacing clinicians, AI augments human expertise by providing evidence-based recommendations that facilitate multidisciplinary cancer care.[4]

The integration of AI into routine oncology practice is gradually giving rise to intelligent clinical ecosystems in which computational models continuously assist physicians throughout diagnosis, treatment planning, disease monitoring, and survivorship management. These developments are expected to play a central role in advancing precision oncology over the coming decades.[5]

2. Evolution of Clinical Artificial Intelligence

Artificial intelligence has undergone remarkable evolution since its initial introduction into healthcare. Early clinical decision-support systems relied primarily on rule-based algorithms that used predefined expert knowledge to assist physicians with limited diagnostic tasks. Although valuable for simple applications, these systems lacked adaptability and were unable to learn from expanding clinical datasets.[6]

The emergence of machine learning introduced data-driven predictive modeling capable of automatically identifying relationships between patient characteristics and clinical outcomes. Algorithms such as decision trees, random forests, support vector machines, and gradient boosting demonstrated considerable success in predicting recurrence, survival, treatment response, and disease progression across multiple cancer types.[7]

Subsequent advances in deep learning dramatically improved performance through automated extraction of complex features from high-dimensional biomedical data. Convolutional neural networks revolutionized medical imaging and digital pathology, while recurrent neural networks improved analysis of longitudinal clinical records and temporal disease progression.

More recently, transformer architectures, multimodal foundation models, graph neural networks, and generative AI have enabled comprehensive integration of imaging, pathology, genomics, laboratory investigations, and clinical documentation into unified computational frameworks that support personalized oncology.[8]

Today, AI has evolved beyond isolated predictive algorithms into intelligent clinical platforms capable of continuously learning from real-world healthcare data while supporting multidisciplinary clinical decision-making.[9]

3. Foundations of Clinical Artificial Intelligence in Oncology

Clinical AI systems operate through multiple interconnected computational layers that transform heterogeneous biomedical information into clinically meaningful predictions. Rather than relying upon individual datasets, these systems integrate radiological imaging, pathology, molecular diagnostics, genomic sequencing, laboratory biomarkers, medication history, treatment records, and electronic health documentation into comprehensive patient representations.[10]

The first stage involves large-scale acquisition of clinical information from hospital information systems, imaging platforms, pathology laboratories, genomic sequencing facilities, pharmacy databases, and wearable monitoring technologies. Subsequent preprocessing pipelines standardize heterogeneous datasets, normalize imaging characteristics, encode clinical narratives using natural language processing, harmonize molecular information, and extract quantitative biomarkers.

Machine learning and deep learning algorithms subsequently analyze these integrated datasets to identify diagnostic patterns, estimate prognosis, predict therapeutic response, and generate individualized risk assessments. Finally, clinical visualization platforms present these predictions through interactive dashboards that support physician interpretation and multidisciplinary decision-making.[11]

This integrated computational architecture enables AI systems to continuously learn from newly acquired patient information while adapting to evolving clinical circumstances.

4. Machine Learning Applications in Oncology

Machine learning remains one of the most widely utilized artificial intelligence techniques in clinical oncology because of its ability to identify complex nonlinear relationships within high-dimensional biomedical datasets. Unlike traditional statistical methods, machine learning algorithms continuously improve predictive performance through experience with expanding clinical information.[12]

Supervised learning models are commonly used for cancer diagnosis, recurrence prediction, toxicity estimation, survival analysis, and therapeutic response prediction. These algorithms learn from labeled datasets

e-ISSN: 3108-2599

to generate accurate individualized predictions Unsupervised learning techniques identify hidden biological subgroups through clustering of genomic, molecular, radiological, and pathological datasets. These discoveries contribute to improved understanding of tumor heterogeneity and facilitate development of more personalized therapeutic strategies.

Semi-supervised and self-supervised learning approaches further improve model performance by utilizing large quantities of unlabeled biomedical data, reducing dependence on expensive manual annotation while enhancing model generalizability across healthcare institutions.[13]

5. Deep Learning in Clinical Cancer Diagnosis

Deep learning has fundamentally transformed cancer diagnosis through automated analysis of complex biomedical images. Deep neural networks learn hierarchical feature representations directly from imaging data, eliminating the need for manually engineered features while substantially improving diagnostic accuracy.[14]

Convolutional neural networks have demonstrated remarkable performance in detecting malignant lesions, classifying tumor subtypes, segmenting anatomical structures, estimating disease stage, and monitoring treatment response across radiology, pathology, dermatology, ophthalmology, and endoscopy.

Deep learning systems also reduce observer variability among clinicians by providing highly reproducible image interpretation. Automated second-opinion analysis improves diagnostic consistency while reducing workload in high-volume oncology centers.

Continuous retraining using expanding clinical datasets enables these algorithms to improve over time, supporting robust diagnostic performance across diverse patient populations and healthcare settings.[15]

6. Artificial Intelligence in Medical Imaging

Medical imaging remains one of the most successful clinical applications of artificial intelligence. Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), mammography, ultrasound, and hybrid imaging collectively generate enormous volumes of diagnostic information that can be efficiently analyzed using AI.[16]

Artificial intelligence assists radiologists by automatically detecting tumors, segmenting lesions, measuring tumor volume, identifying metastatic disease, and evaluating therapeutic response. Radiomics further enhances clinical interpretation by extracting quantitative imaging biomarkers describing tumor morphology, texture, vascularity, shape, and spatial heterogeneity.

Longitudinal image analysis allows AI to compare sequential imaging examinations throughout treatment, applicable across diverse cancer types. identifying subtle radiological changes that may indicate early therapeutic response or disease progression before they become visually apparent. These capabilities support more timely treatment modification and personalized patient management.[17]

7. Digital Pathology and Computational Histopathology

Digital pathology has become a major pillar of clinical artificial intelligence by transforming conventional microscope slides into high-resolution digital images suitable for computational analysis. Whole-slide imaging enables AI systems to simultaneously evaluate millions of microscopic tissue regions, providing objective assessment of tumor morphology, cellular differentiation, stromal remodeling, immune infiltration, necrosis, and angiogenesis.[18]

Deep learning and transformer-based pathology models accurately classify tumor subtypes, estimate histological grade, identify prognostic biomarkers, and predict metastatic potential with high reproducibility. These technologies improve diagnostic consistency while reducing interobserver variability among pathologists.

An important recent innovation involves prediction of molecular biomarkers directly from histopathological images. AI models have demonstrated the ability to infer clinically significant alterations—including EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression—from routine tissue morphology, potentially accelerating precision oncology workflows and reducing dependence on costly molecular testing.[19]

Computational pathology also enables quantitative evaluation of the tumor microenvironment, providing clinically valuable information regarding immune-cell distribution, fibrosis, vascular remodeling, and stromal organization.

8. Artificial Intelligence in Genomic Medicine

Advances in next-generation sequencing have generated increasingly complex genomic datasets requiring sophisticated computational interpretation. Artificial intelligence plays a central role in identifying clinically actionable mutations, prioritizing genomic variants, predicting drug sensitivity, estimating resistance mechanisms, and classifying tumors according to molecular characteristics.[20]

Machine learning integrates genomic information with transcriptomics, proteomics, radiological imaging, pathology, laboratory biomarkers, and clinical variables to generate comprehensive patient-specific therapeutic recommendations. AI-assisted genomic interpretation accelerates molecular tumor board discussions while improving implementation of precision medicine across diverse malignancies.

As global genomic databases continue to expand, artificial intelligence will become increasingly essential for translating complex molecular information into clinically actionable insights that improve diagnosis, prognosis, and treatment selection.[21]

9. Radiogenomics and Multimodal Clinical Intelligence

Radiogenomics represents one of the most promising applications of clinical artificial intelligence by integrating quantitative imaging biomarkers with genomic and molecular information. AI identifies relationships between imaging phenotypes and underlying biological pathways, enabling non-invasive prediction of clinically significant genetic alterations using routinely acquired radiological studies.[22]

Multimodal learning further strengthens precision oncology by simultaneously integrating imaging, pathology, genomics, laboratory investigations, clinical documentation, and treatment history into unified computational models. These comprehensive patient representations improve diagnostic accuracy, prognostic prediction, and therapeutic selection while supporting individualized cancer management.

As multimodal AI systems continue to mature, they are expected to become fundamental components of future intelligent oncology clinics capable of delivering increasingly personalized and evidence-based cancer care.

10. Artificial Intelligence in Personalized Cancer Therapy

One of the greatest opportunities presented by clinical artificial intelligence is the ability to individualize cancer therapy based on patient-specific biological and clinical characteristics. Conventional treatment decisions are primarily guided by population-based evidence, whereas AI integrates genomic alterations, pathological findings, radiological imaging, laboratory biomarkers, treatment history, and comorbidities to generate personalized therapeutic recommendations.[23]

Machine learning algorithms estimate treatment response, recurrence probability, progression-free survival, overall survival, and treatment-related toxicity across various therapeutic options. These predictive models assist oncologists in selecting optimal chemotherapy regimens, targeted therapies, endocrine therapies, immunotherapies, radiation schedules, and multimodal treatment combinations while minimizing unnecessary adverse effects.

Rather than replacing physicians, AI functions as an advanced clinical decision-support system that complements multidisciplinary expertise and improves precision in individualized cancer management.

11. Artificial Intelligence in Immuno-Oncology

Immunotherapy has revolutionized cancer treatment, yet predicting patient response remains one of the greatest challenges in precision oncology. Artificial intelligence addresses this problem by integrating genomic mutations, tumor mutational burden, PD-L1 expression, tumor-infiltrating lymphocytes, digital pathology, radiological imaging, circulating biomarkers, and clinical variables into comprehensive predictive models.[24]

Deep learning algorithms accurately characterize the tumor microenvironment by quantifying immune-cell distribution, stromal architecture, inflammatory signaling pathways, and spatial cellular interactions. These analyses improve identification of patients most likely to benefit from immune checkpoint inhibitors while reducing unnecessary exposure to treatment-related toxicities.

Future AI systems are expected to support optimization of CAR-T cell therapies, cancer vaccines, bispecific antibodies, adoptive cellular therapies, and combination immunotherapeutic strategies through continuous learning from real-world clinical outcomes.

12. Artificial Intelligence in Radiation Oncology

Radiation oncology has become one of the most successful clinical applications of artificial intelligence. Modern AI systems automate labor-intensive processes including tumor segmentation, organ-at-risk delineation, treatment planning, dose optimization, image registration, and quality assurance.[25]

Deep learning algorithms significantly reduce contouring time while improving consistency among radiation oncologists. AI also supports adaptive radiotherapy by continuously analyzing sequential imaging acquired during treatment, allowing radiation plans to be modified according to changes in tumor size, patient anatomy, and normal tissue positioning.

These intelligent planning systems improve treatment precision, reduce radiation exposure to healthy tissues, enhance workflow efficiency, and contribute to improved patient outcomes.

13. Artificial Intelligence in Drug Discovery and Clinical Trials

Development of anticancer therapies remains expensive, time-consuming, and associated with high failure rates. Artificial intelligence is accelerating drug discovery by analyzing molecular pathways, protein interactions, genomic alterations, pharmacological databases, and chemical structures to identify promising therapeutic candidates.[26]

Generative AI models further enhance pharmaceutical research by designing novel drug molecules, predicting drug-target interactions, estimating toxicity profiles, and

identifying biomarkers associated with treatment response.
stratification, endpoint prediction, and outcome analysis. By improving trial efficiency and reducing variability, AI has the potential to accelerate regulatory approval of innovative oncology therapeutics while reducing development costs.

14. Clinical Decision Support Systems

Artificial intelligence-powered clinical decision-support systems are becoming integral components of modern oncology practice. These platforms continuously integrate laboratory investigations, radiological imaging, pathology reports, genomic sequencing, medication records, treatment history, and electronic health records into unified clinical workflows.[27]

Natural language processing automatically extracts clinically relevant information from physician notes, pathology reports, discharge summaries, multidisciplinary meeting documentation, and scientific literature. AI subsequently synthesizes these heterogeneous datasets into evidence-based recommendations that assist clinicians in diagnosis, therapeutic planning, toxicity prediction, and long-term patient management.

Interactive dashboards provide individualized risk assessments, predicted treatment responses, survival probabilities, and evidence-supported clinical pathways, facilitating multidisciplinary collaboration while reducing administrative burden.

15. Challenges, Ethics, and Explainable Artificial Intelligence

Despite remarkable technological progress, widespread clinical implementation of AI remains constrained by several scientific, technical, ethical, and regulatory challenges. Explainable artificial intelligence (XAI) has emerged as a critical area of research because clinicians require transparent explanations for AI-generated recommendations before incorporating them into high-stakes medical decisions.[28]

Visualization techniques including saliency maps, attention heatmaps, SHAP (Shapley Additive Explanations), feature attribution methods, and counterfactual explanations improve model interpretability by identifying variables that contribute most strongly to clinical predictions.

Additional challenges include algorithmic bias resulting from non-representative datasets, data heterogeneity, interoperability limitations, cybersecurity threats, patient privacy, informed consent, regulatory approval,

Clinical trials also benefit from AI-assisted patient recruitment, eligibility screening, treatment
medico-legal accountability, and unequal access to advanced computational technologies. Addressing these barriers will require standardized validation protocols, transparent governance frameworks, multidisciplinary collaboration, and continuous physician oversight.

16. Future Directions

The future of clinical artificial intelligence in oncology is expected to involve increasingly integrated intelligent healthcare ecosystems that combine multimodal foundation models, wearable health technologies, liquid biopsy, robotic surgery, cloud computing, digital pathology, molecular diagnostics, and continuously learning healthcare systems.[29]

Foundation models trained on massive biomedical datasets will provide generalized clinical reasoning across radiology, pathology, genomics, laboratory medicine, and electronic health records. Generative AI will accelerate scientific discovery through automated literature synthesis, molecular design, protein structure prediction, synthetic biomedical data generation, and personalized patient education.

International collaboration among clinicians, engineers, computer scientists, molecular biologists, healthcare organizations, and regulatory agencies will be essential to ensure responsible, equitable, and clinically validated implementation of AI technologies worldwide.

17. Discussion

Clinical artificial intelligence has evolved from experimental computational models into practical technologies capable of supporting nearly every stage of oncology care. Applications in cancer diagnosis, prognostic prediction, precision medicine, immunotherapy, radiation oncology, digital pathology, genomic medicine, drug discovery, and clinical decision support demonstrate the transformative potential of AI within modern healthcare.

Nevertheless, successful integration into routine clinical practice requires overcoming important barriers involving data quality, interoperability, computational infrastructure, clinician education, regulatory oversight, cybersecurity, and ethical governance. High-quality multicenter validation studies, standardized reporting guidelines, explainable algorithms, and prospective clinical trials will be essential to establish trust and ensure safe implementation of AI-assisted oncology systems.[30]

18. Conclusion

Artificial intelligence is fundamentally reshaping clinical oncology by enabling more accurate diagnosis, personalized prognostic assessment, individualized treatment planning, and evidence-based clinical decision-making. Through integration of radiology, pathology, genomics, molecular biology, electronic health records, and advanced computational modeling, AI supports precision oncology across the entire continuum of cancer care.

artificial intelligence, and cloud-based healthcare infrastructure will further expand the capabilities of intelligent clinical systems. Although technical, ethical, regulatory, and implementation challenges remain, continued interdisciplinary collaboration is expected to accelerate responsible adoption of AI into routine oncology practice.

Future advances in multimodal learning, foundation models, explainable AI, federated learning, generative Rather than replacing clinicians, clinical artificial intelligence will continue to augment human expertise, improve healthcare efficiency, enhance precision medicine, and ultimately contribute to better patient outcomes, making it one of the defining innovations in the future of cancer care.

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.
3. Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.
4. Boehm, K.M. et al. (2022) ‘Harnessing Multimodal Data Integration to Advance Precision Oncology’, Nature Reviews Cancer, 22(2), pp. 114–126.
5. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
6. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
7. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
8. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
9. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
10. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
11. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
12. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
13. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
14. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System

Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 ,

15. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
16. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
17. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
18. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
19. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
20. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

DOI: https://doi.org/10.46121/pspc.51.4.7

21. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
22. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
23. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
24. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
25. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
26. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
27. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
28. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
29. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
30. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.